🔎 Trials Near Me

Hjem › Burkitts lymfom › Oregon

Kliniske studier for Burkitts lymfom i Oregon

8 studier for Burkitts lymfom søker deltakere på steder i Oregon.

Byer i Oregon

Offisiell studietekst (engelsk)

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • og 1 flere
RekruttererFase 3
Alder 18 til 39 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT03739814

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Oregon Health and Science University ( Site 1004), Portland
RekruttererFase 1/2
6 Months – 25 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
RekruttererFase 2
Alder 1 til 30 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
RekruttererFase 3
365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Oregon Health & Science University, Portland
RekruttererFase 2
Alder 7 til 25 · Alle kjønn · Oppdatert 19. aug. 2026 · NCT05082519

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Oregon Health & Science University, Portland
RekruttererFase 1/2
Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Oregon Health and Science University - Knight Cancer Institute, Portland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. feb. 2026 · NCT05544019

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.